← Back to Search

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

N/A

Recruiting

Led By Sapna Syngal, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

No Placebo-Only Group

Summary

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Eligible Conditions

Bladder Cancer
Barrett's Esophagus
Bone cysts
Breast cancer
Prostate Cancer
Mole
Osteoclastoma
Osteochondromas
Lung Cancer
Cancer Predisposition Syndrome
Endometrial Neoplasia
Vulvar Intraepithelial Neoplasia
Nephrogenic Rest Syndrome
Adenomatous Hyperplasia
Oral Precancerous Diseases
Cervical and Endocervical Carcinoma
Spitz Nevus
Smoking History
Liver Cirrhosis
Adult Cancer Survivors
Cancer Risk
Carcinogens
Osteochondroma
Cancer Predisposition
Childhood Cancer Survivors
Pancreatic Lesions
Tubal Intraepithelial Carcinoma
Blood Cancers
Colonic Adenomas
Non-alcoholic Fatty Liver Disease
Lung Nodules

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Malignant Neoplasms

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: PRECURSOR LESIONSExperimental Treatment1 Intervention

Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

Group II: HEREDITARY RISKExperimental Treatment1 Intervention

Group III: FAMILY MEMBERSExperimental Treatment1 Intervention

These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant

Group IV: EXPOSED HIGH RISKExperimental Treatment1 Intervention

Do I qualify?Apply below to find out